Global Perspectives: Current and Future State of CAR T 2021
Expert perspectives and strategic insights on new and relevant clinical advances of CAR T in DLBCL, ALL, FL, and MCL, including recently presented abstracts at ASCO and EHA.
FACULTY CO-CHAIR
Marie José Kersten, MD, PhD
Academic Medical Center – University of Amsterdam, The Netherlands
FACULTY CO-CHAIR
Frederick Locke, MD
Moffitt Cancer Center, Tampa, FL, USA
FACULTY MEMBERS
Catherine Thieblemont, MD, PhD
Hôpital Saint-Louis, Paris, France
Julio Delgado, MD, PhD
ICMHO, Hospital Clínic de Barcelona, Barcelona, Spain
Max Topp, MD
University Hospital, Würzburg, Germany
Jae Park, MD
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Matthew Frigault, MD
Massachusetts General Hospital, Boston, MA, USA
Gareth Morgan, MD, PhD
NYU Langone Medical Center, New York, NY, USA
Julio Chavez, MD
Moffitt Cancer Center, Tampa, FL, USA
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- Update on CAR T in DLBCL
- Update on CAR T in ALL
- Update on CAR T in FL and MCL
- BCMA-Targeting Agents in MM
- Current State and Future Directions in CAR T Manufacturing
- Next-Generation CARs
- Advances in “Off-the-Shelf” CAR T-Cell Therapy
